{"id":"https://openalex.org/W2772962529","doi":"https://doi.org/10.1021/acs.jmedchem.7b01411","title":"Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus","display_name":"Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus","publication_year":2017,"publication_date":"2017-12-13","ids":{"openalex":"https://openalex.org/W2772962529","doi":"https://doi.org/10.1021/acs.jmedchem.7b01411","mag":"2772962529","pmid":"https://pubmed.ncbi.nlm.nih.gov/29236497"},"language":"en","primary_location":{"id":"doi:10.1021/acs.jmedchem.7b01411","doi":"https://doi.org/10.1021/acs.jmedchem.7b01411","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.jmedchem.7b01411","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025992004","display_name":"Chafiq Hamdouchi","orcid":"https://orcid.org/0000-0001-7683-2012","observed_orcids":["https://orcid.org/0000-0001-7683-2012","https://orcid.org/0000-0002-9625-6566"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Chafiq Hamdouchi","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":"https://orcid.org/0000-0001-7683-2012","affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072268460","display_name":"Pranab Maiti","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pranab Maiti","raw_affiliation_strings":["Jubilant Biosys Research Center, Bangalore, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jubilant Biosys Research Center, Bangalore, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015278520","display_name":"Alan M. Warshawsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alan M. Warshawsky","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002798100","display_name":"Amy C. DeBaillie","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy C. DeBaillie","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038187833","display_name":"Keith A. Otto","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keith A. Otto","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012679202","display_name":"Kelly L. Wilbur","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kelly L. Wilbur","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082570154","display_name":"Steven D. Kahl","orcid":"https://orcid.org/0000-0001-7085-9556","observed_orcids":["https://orcid.org/0000-0001-7085-9556"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven D. Kahl","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033656485","display_name":"Anjana Patel Lewis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anjana Patel Lewis","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109508256","display_name":"Guemalli R. Cardona","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guemalli R. Cardona","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022245179","display_name":"Richard W. Zink","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard W. Zink","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103200879","display_name":"Keyue Chen","orcid":"https://orcid.org/0000-0002-1321-6121","observed_orcids":["https://orcid.org/0000-0002-1321-6121"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keyue Chen","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014340525","display_name":"Siddaramaiah CR","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Siddaramaiah CR","raw_affiliation_strings":["Jubilant Biosys Research Center, Bangalore, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jubilant Biosys Research Center, Bangalore, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028384070","display_name":"Jayana P. Lineswala","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jayana P. Lineswala","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012846205","display_name":"Grace L. Neathery","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Grace L. Neathery","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029117631","display_name":"Cecilia G. Bouaichi","orcid":"https://orcid.org/0000-0002-5301-0961","observed_orcids":["https://orcid.org/0000-0002-5301-0961"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cecilia Bouaichi","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057594087","display_name":"Benjamin A. Diseroad","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Benjamin A. Diseroad","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103520035","display_name":"Alison N. Campbell","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alison N. Campbell","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023027409","display_name":"Stephanie A. Sweetana","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephanie A. Sweetana","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111916273","display_name":"Lisa A. Adams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa A. Adams","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065870082","display_name":"Over Cabrera","orcid":"https://orcid.org/0009-0002-7912-8420","observed_orcids":["https://orcid.org/0009-0002-7912-8420"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Over Cabrera","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055547863","display_name":"Xiaosu Ma","orcid":"https://orcid.org/0000-0002-6223-8140","observed_orcids":["https://orcid.org/0000-0002-6223-8140"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaosu Ma","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050440985","display_name":"Nathan P. Yumibe","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nathan P. Yumibe","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068146796","display_name":"Chahrzad Montrose\u2010Rafizadeh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chahrzad Montrose-Rafizadeh","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075934968","display_name":"Yanyun Chen","orcid":"https://orcid.org/0009-0007-6327-7997","observed_orcids":["https://orcid.org/0009-0007-6327-7997"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yanyun Chen","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5103359547","display_name":"Anne Reifel Miller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Reifel Miller","raw_affiliation_strings":["Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lilly\rResearch Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, DC: 0540, Indianapolis, Indiana 46285, United States","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5025992004"],"corresponding_institution_ids":["https://openalex.org/I168537998"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":2.5921,"has_fulltext":false,"cited_by_count":32,"citation_normalized_percentile":{"value":0.90883409,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"61","issue":"3","first_page":"934","last_page":"945"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9526000022888184,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9526000022888184,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Synthesis and biological activity","score":0.016599999740719795,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10839","display_name":"Pancreatic function and diabetes","score":0.0142000000923872,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gpr40-agonist","display_name":"GPR40 agonist","score":0.984000027179718},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9670000076293945},{"id":"https://openalex.org/keywords/glucose-dependent-insulin-secretion","display_name":"glucose-dependent insulin secretion","score":0.7720000147819519},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7170000076293945},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.8339999914169312},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.7440000176429749},{"id":"https://openalex.org/keywords/tetrahydroquinoline-derivatives","display_name":"tetrahydroquinoline derivatives","score":0.8769999742507935},{"id":"https://openalex.org/keywords/fused-heterocycles","display_name":"fused heterocycles","score":0.8019999861717224},{"id":"https://openalex.org/keywords/n-dealkylation","display_name":"N-dealkylation","score":0.7900000214576721},{"id":"https://openalex.org/keywords/o-dealkylation","display_name":"O-dealkylation","score":0.9049999713897705}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7971319556236267},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.7963664531707764},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7121492624282837},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.6666131019592285},{"id":"https://openalex.org/C32670627","wikidata":"https://www.wikidata.org/wiki/Q18026423","display_name":"Free fatty acid receptor 1","level":4,"score":0.5937130451202393},{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.49023300409317017},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.4568650424480438},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.44189339876174927},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.4127247631549835},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.4101518988609314},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.33877962827682495},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3242051303386688},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.23611903190612793},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.2295767068862915},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.22400936484336853},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.15844249725341797}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004285","descriptor_name":"Dogs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D014230","descriptor_name":"Triazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D043562","descriptor_name":"Receptors, G-Protein-Coupled","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1021/acs.jmedchem.7b01411","doi":"https://doi.org/10.1021/acs.jmedchem.7b01411","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.jmedchem.7b01411","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:29236497","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29236497","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1193047888","https://openalex.org/W1964318145","https://openalex.org/W1974290383","https://openalex.org/W1999927420","https://openalex.org/W2012325805","https://openalex.org/W2012852739","https://openalex.org/W2019925176","https://openalex.org/W2039688371","https://openalex.org/W2048922467","https://openalex.org/W2054951377","https://openalex.org/W2061650356","https://openalex.org/W2073474683","https://openalex.org/W2077936393","https://openalex.org/W2080483538","https://openalex.org/W2088522673","https://openalex.org/W2089540591","https://openalex.org/W2098082048","https://openalex.org/W2102964449","https://openalex.org/W2109477582","https://openalex.org/W2128326754","https://openalex.org/W2138309074","https://openalex.org/W2147024197","https://openalex.org/W2156398717","https://openalex.org/W2163448046","https://openalex.org/W2323197290","https://openalex.org/W2532977935"],"related_works":["https://openalex.org/W2048922467","https://openalex.org/W2532977935","https://openalex.org/W2896825249","https://openalex.org/W2033060150","https://openalex.org/W2889131977","https://openalex.org/W2326770901","https://openalex.org/W1633693743","https://openalex.org/W2054951377","https://openalex.org/W2886217649","https://openalex.org/W2783761530"],"abstract_inverted_index":{"As":[0],"a":[1,142],"part":[2],"of":[3,12,40,116,129,138],"our":[4,25],"program":[5],"to":[6,69],"identify":[7],"potent":[8],"GPR40":[9],"agonists":[10],"capable":[11],"being":[13],"dosed":[14],"orally":[15],"once":[16],"daily":[17],"in":[18,91,102,124],"humans,":[19],"we":[20],"incorporated":[21],"fused":[22],"heterocycles":[23],"into":[24],"recently":[26],"disclosed":[27],"spiropiperidine":[28],"and":[29,35,43,61,65,76,86,98,118,132],"tetrahydroquinoline":[30],"acid":[31,71],"derivatives":[32,72],"1,":[33],"2,":[34],"3":[36],"with":[37,73],"the":[38,45,58,63],"intention":[39],"lowering":[41],"clearance":[42],"improving":[44],"maximum":[46],"absorbable":[47],"dose":[48],"(Dabs).":[49],"Hypothesis-driven":[50],"structural":[51],"modifications":[52],"focused":[53],"on":[54],"moving":[55],"away":[56],"from":[57,94],"zwitterion-like":[59],"structure.":[60],"mitigating":[62],"N-dealkylation":[64],"O-dealkylation":[66],"issues":[67],"led":[68],"triazolopyridine":[70],"unique":[74],"pharmacology":[75,131],"superior":[77],"pharmacokinetic":[78,133],"properties.":[79],"Compound":[80],"4":[81],"(LY3104607)":[82],"demonstrated":[83],"functional":[84],"potency":[85],"glucose-dependent":[87],"insulin":[88],"secretion":[89],"(GDIS)":[90],"primary":[92],"islets":[93],"rats.":[95],"Potent,":[96],"efficacious,":[97],"durable":[99],"dose-dependent":[100],"reductions":[101],"glucose":[103,108],"levels":[104],"were":[105,122],"seen":[106],"during":[107],"tolerance":[109],"test":[110],"(GTT)":[111],"studies.":[112],"Low":[113],"clearance,":[114],"volume":[115],"distribution,":[117],"high":[119],"oral":[120],"bioavailability":[121],"observed":[123],"all":[125],"species.":[126],"The":[127],"combination":[128],"enhanced":[130],"properties":[134],"supported":[135],"further":[136],"development":[137],"this":[139],"compound":[140],"as":[141],"potential":[143],"glucose-lowering":[144],"drug":[145],"candidate.":[146]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":4}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-12-22T00:00:00"}